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Nitric Oxide Modulates MCP-1 Expression in Endothelial
Cells: Implications for the Pathogenesis of Pulmonary
Granulomatous Vasculitis
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Abstract—Monocyte chemoattractant protein-1 (MCP-1) is a pivotal mediator of angiocentric gran-
uloma formation in glucan-induced pulmonary granulomatous vasculitis. Based on the rationale that
mononuclear phagocytes retrieved from granulomas are rich sources of nitric oxide (NO) and that the
recruitment of mononuclear phagocytes into lesions abates as granuloma formation slows, we tested
the hypothesis that MCP-1 gene expression is regulated by a NO-sensitive mechanism. Preexposure
of endothelial cell (EC) monolayers to NO donor compounds markedly reduced cytokine-induced
MCP-1 expression and cytosolic-to-nuclear translocation of nuclear factor-kappa B (NF-κB), reversed
fluctuations in endothelial reduced glutathione (GSH) pools but did not affect cGMP concentrations.
The lungs of mice bearing targeted disruptions of the inducible nitric oxide synthase (iNOS) gene
exhibited significantly higher concentrations of MCP-1 following glucan infusion than did those of
wild-type mice. Cumulatively, these data suggest that NO suppresses MCP-1 expression by blunting
the redox changes associated with cytokine-induced EC activation.
KEY WORDS: monocyte chemoattractant protein-1; pulmonary granulomatous vasculitis; nitric oxide; endothe-
lial cells; iNOSknockout mice.
INTRODUCTION
Pulmonary granulomas develop in response to a va-
riety of microbial agents (eg.Mycobacterium tuber-
culosis), inhaled foreign particulates (e.g. metal dusts
such as beryllium), and etiologically unknown factors
(e.g. Wegener’s granulomatosis, sarcoidosis) (1). Sev-
eral forms of pulmonary granulomas are characterized
by monocyte/macrophage-rich collections of inflamma-
tory cells centered around blood vessels (i.e. angiocen-
tric). Monocyte chemoattractant protein-1 (MCP-1), a
member of the C-C or beta subfamily of chemokines
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has been identified as a pivotal mediator of granu-
loma formation. Secreted by a variety of cell types, in-
cluding endothelial cells (ECs), smooth muscle cells,
fibroblasts, and monocytes, MCP-1 induces monocyte re-
cruitment and activation, and can upregulate adhesion
molecule expression and cytokine production by mono-
cytes (2). Monocyte chemoattractant protein-1 can acti-
vate monocytes by inducing calcium flux and a respiratory
burst (3).
Our previous studies have revealed that vascular wall
MCP-1 expression is obligatory for lesion development
in a rodent model of pulmonary granulomatous vasculitis
(4). In this model, the intravenous infusion of particulate
yeast cell wall glucan results in the rapid, synchronous
development of foreign-body-type granulomas that, when
fully mature, are composed primarily of monocytes and
macrophages. Recent studies indicate that the upregu-
lation of MCP-1 is, in part, regulated by the cytokines
TNF-α and IL-1β (5). MCP-1 expression during the
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pathogenesis of glucan-induced granuloma formation is
biphasic with an early (1 h) blood-vessel wall associated
rise in MCP-1 and a later (6–24 h) rise in MCP-1
associated with granuloma cellsper se(6). Experiments
in which neutrophils have been either selectively de-
pleted or their adherence to vascular wall endothelium
inhibited by means of infused sialyl-Lewis glycomimetic
P-selectin antagonists have revealed that neutrophils
are obligatory for full granuloma development even
though they are not present in definitive lesions (48–96 h)
(7, 8). These observations, coupled with evidence that
the infusion of catalase inhibits granuloma formation
and that pharmacologic modulation of intracellular
glutathione redox status modulates MCP-1 expression
in granulomatous vasculitis, support the hypothesis that
neutrophils and locally produced H2O2 are important
mediators of monocyte recruitment (9).
While there is extensive evidence suggesting that
the expression of proinflammatory mediators including
MCP-1, is redox sensitive, the intracellular mediators and
transduction pathway(s) are complex and incompletely
understood (10). In this study, we tested the hypothesis that
locally produced NO regulates the expression of endothe-
lial MCP-1. The rationale for this hypothesis in the context
of glucan-induced granulomatous vasculitis rests on evi-
dence that mononuclear phagocytes in pulmonary lesions
release NO discretely at sites of granuloma formation. In
this scenario, NO may temporally and anatomically de-
limit the extent of an evolving granulomatous lesion by
either down-regulating further MCP-1 elaboration and/or
by preventing MCP-1 expression in vessel wall cells ad-
jacent to the lesion. In the present context, “delimitation”
indicates the cessation of net “growth” of a granuloma.
While there is likely to be an overlap in processes, develop-
ment of an individual granuloma must reach a maximum
size before it begins to then “resolve”. Thein vitro data
presented suggest that locally produced NO may regu-
late endothelial MCP-1 expression by blunting cytokine-
and/or reactive oxygen intermediate-induced changes in
cellular redox status.
MATERIALS AND METHODS
Unless otherwise specified, materials were pur-
chased from Sigma Chemical Company (St. Louis, MO).
NONOates were purchased from Cayman Chemicals
(Ann Arbor, MI). Mice were obtained from Jackson Lab-
oratories (Bar Harbor, ME).
Endothelial Cell Culture
Human umbilical vein endothelial cells (HUVECs)
were isolated from umbilical cords as previously
described (11).
Treatment of HUVECs for Enzyme Immunoassay
(EIA) Experiments
Aqueous solutions of NO were generated using
NONOate compounds. NONOates are nucleophilic NO
adducts that spontaneously decompose at neutral pH to
release NO (12). As indicated in the results, we em-
ployed combinations of two short half-life NO donors,
Methylamine hexamethylene methylamine (MAHMA)
NONOate (t1/2 = 1 min at 37◦C) and Diethylamine
(DEA) NONOate (t1/2 = 2 min at 37◦C), or Dipropy-
lenetriamine (DPTA) NONOate (t1/2 = 3 h at 37◦C) for
longer sustained release. NONOate stock solutions were
prepared in 0.01 N NaOH and then diluted into M199
medium to initiate NO release. After a 30-min exposure
to NO, HUVECs were stimulated with either TNF-α or
IL-1β(1 ng/mL) for 8 h. The conditioned media collected
at the end of this 8-h incubation period were subjected to
an MCP-1 enzyme immunoassay (EIA). Cell viability was
assessed by using a fraction of the conditioned media from
the EIA experiment in a cytotoxicity detection (LDH) as-
say (Boehringer, Mannheim, Germany). Cell viability was
always≥95%.
MCP-1 Enzyme Immunoassay (EIA)
MCP-1 EIAs were carried out as previously
decribed (13).
Ribonuclease (RNase) Protection Assay
Total RNA was extracted from endothelial cells
using Tri Reagent according to manufacturer’s in-
structions. The RNase protection assays were per-
formed using the RiboQuant Multi-probe kit from
Pharmingen (San Diego, CA) and carried out as previously
described (13).
Extraction of Nuclear Protein
Nuclear extracts were prepared and protein concen-
trations determined as previously decribed (9, 14).
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Electrophoretic Mobility Shift Assay
Electrophoretic mobility shift assays (EMSAs) were
carried out as previously described using a gel shift assay
system kit (Promega, Madison, WI) (11).
Glutathione Assay
The glutathione assay was performed using a kit from
Oxis International (Portland, OR) following the manu-
facturer’s instructions. Briefly, cells were washed with
phosphate buffered saline (PBS) and homogenized in ice-
cold 5% metaphosphoric acid. The homogenate was cen-
trifuged and the resulting aqueous layer was utilized for the
assay. Reduced glutathione (GSH) was utilized as a stan-
dard. Spectrophotometric determinatons were performed
in triplicate using a Elx808 plate reader set to a wavelength
of 405 nm.
Induction of Pulmonary Granulomatosis
Glucan-induced pulmonary granulomatous vasculi-
tis was induced in BL6 mice oriNOSknockout mice as
previously decribed (4). Briefly, glucan from Bakers yeast
(Sigma) was suspended in phosphate bufferered saline
(5 mg glucan in 1 mL of PBS). The suspension was son-
icated, vortexed, and 100µL were infused slowly via the
heat-dilated tail vein. Control animals received vehicle
(PBS) only. At specified intervals following glucan ad-
ministration, animals were euthanized and their lungs and
hearts removeden bloc. One lung was instilled with 10%
buffered formalin phosphate (Fisher Scientific, Pittsburgh,
PA), followed by processing for light and electron mi-
croscopy. The other lung was immediately snap-frozen
in liquid nitrogen and subsequently processed for use in
EIAs of tissue extracts.
cGMP Assay
cGMP concentrations were measured with a kit from
Assay Designs (Ann Arbor, MI) according to manufac-
turer’s instructions. Briefly, HUVECs that had been grown
in 24-multiwell plates were washed with HBSS to re-
move traces of serum. The cells were incubated with the
indicated test compounds for 15 min and subsequently
1 mM isobutylmethylxanthine (IBMX) was added to in-
hibit the phosphodiesterases (5-min incubation). Hank’s
balance salt solution (HBSS) was then aspirated and
250 µL of 0.1 N hydrochloric acid (HCl) were added
to each well to stop enzymatic reactions and to extract
cGMP. After 30 min, the HCl extract was collected and
stored until analyzed. To normalize cGMP values, the pro-
tein content in each well was measured by the Bradford
method after solubilization with 1 N sodium hydroxide
(NaOH).
Densitometric Scanning
Autoradiographs from RNase protection assays and
EMSAs were scanned using Polaroid PhotoMAX Pro and
integrated densities were determined using Scion Image
for windows (Scion Corporation, Frederick, MD). To ad-
just for differences in sample loading between wells in
the RNase protection assay, MCP-1 mRNA levels were
expressed as ratios of integrated densities for MCP-1 to
GAPDH products.
Statistical Analysis
Statistical analysis was performed using SAS, ver-
sion 8.2 (SAS Institute). All values are expressed as the
means± standard error. Data were analyzed by analysis of
variance (ANOVA).(15) Probability (p) values of<0.05
were considered significant.
RESULTS
Exogenous NO Suppresses Cytokine-Induced
MCP-1 in HUVECS
Exposure of HUVECs to either TNF-α or IL-1β re-
sulted in dose-dependent increases in MCP-1 production
(Fig. 1). When cytokine-activated cells were pretreated
with a combination of the short half-life donors MAHMA-
NONOate (t1/2 = 1 min at 37◦C) (50 µM) and DEA
NONOate (t1/2 = 2 min) (50µM), significant reductions
in secreted MCP-1 concentrations were observed. These
effects were not observed when the NO donor compound
and the cytokine were added simultaneously or when NO
exposure followed cytokine stimulation (data not shown).
Similar results were observed when the NO donor, DPTA-
NO (t1/2 = 3 h at 37◦C) (50µM) was substituted for DEA-
NO (data not shown). These data indicate that exposure
of HUVECs to chemically generated NO prior to stimu-
lation with TNF-α or IL-1β results in marked reductions
in MCP-1 production.
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Fig. 1. Suppression of cytokine-induced MCP-1 by exogenous NO. HUVECs were treated for 30 min with medium alone (◦) r NONOate (¤),
respectively, followed by a 12-h incubation period with either a) TNF-α or b) IL-1β. These data represent means± SE of a single experiment that
is representative of four separate experiments. In each experiment, conditions were examined in triplicate. Asterisk∗ denotes significant difference in
MCP-1 concentrations in presence and absence of NO donor.
NO Donors Suppress MCP-1 mRNA
In order to determine whether the observed decreases
in cytokine-induced MCP-1 protein secretion in response
to NO pretreatment were also associated with changes in
MCP-1 mRNA concentrations, we utilized a multi-probe
RNase protection assay. No MCP-1 mRNA was detectable
in either medium-treated HUVECs or HUVECs that had
been treated with a combination of MAHMA and DEA
NONOates (Fig. 2). As expected, exposure of HUVECs
to TNF-α or IL-1β (4 h) resulted in marked increases in
MCP-1 mRNA concentrations (Fig. 2). When cells were
treated with MAHMA and DEA NONOates prior to cy-
tokine stimulation significant reductions in MCP-1 mRNA
were observed when compared to HUVECs exposed to cy-
tokines alone (Fig. 2). These observations indicate that the
NO-mediated reductions in MCP-1 protein production in
HUVECs measured by EIA (Fig. 1) are accompanied by
reduced MCP-1 mRNA levels.
Exogenous NO Suppresses Cytokine-Induced NF-κB
Translocation but Does Not Affect AP-1 Activation
Cytokine-induced MCP-1 gene expression in
endothelial cells depends on the cooperative interaction
of the redox-sensitive transcription factors NF-κB and
AP-1 (16). We examined the activation of NF-κB and
AP-1 by EMSA (Fig. 3). Low concentrations of NF-κB
were detected in nuclear extracts derived from media-
treated cells (lane 1, Fig. 3A). As expected, cytokine
stimulation of HUVECs resulted in a marked increase in
the cytosolic-to-nuclear translocation of NF-κB (lanes 2
and 3, Fig. 3A). The activation of NF-κB was suppressed
by pretreatment with MAHMA and DEA NONOates
(lanes 5 and 6, Fig. 3A). No changes in the nuclear
concentrations of AP-1 were observed in endothelial cells
upon activation by cytokines (lanes 2 and 3 compared
to lane 1; Fig. 3B). Moreover, NO donors had no effect
on activation of AP-1 (lanes 4, 5, and 6; Fig. 3B).
These data indicate that cytokine-induced activation of
NF-κB but not AP-1, is sensitive to NO exposure. Since
NF-κB is a redox-sensitive transcription factor, these data
suggest that alterations of cellular redox status may be
mechanistically important in NO-mediated suppression
of endothelial MCP-1 production.
Exogenous NO Blunts Cytokine-Induced
Fluctuations in Endothelial Reduced
Glutathione (GSH) Concentrations
In order to further address the potential role of
changes in cellular redox status as a mechanism for
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Fig. 2. Suppression of cytokine-induced MCP-1 mRNA concentrations by exogenous NO. HUVECs were treated for
30 min with medium (SFM) or a combination of MAHMA NONOate and DEA NONOate (50µM each), followed by
a 4-h incubation period with TNF-α or IL-1β. RNase protection assay was utilized in order to detect specific transcripts
for MCP-1 and for the “housekeeping” genes,L32 andGAPDH, as controls. The data shown are representative of
three separate experiments.
NO-mediated suppression of MCP-1 expression, we ex-
amined the effects of cytokines and NO on cellular GSH
concentrations. TNF-α treatment of HUVECs resulted in
a 30% decrease in intracellular GSH concentration when
compared to cells treated with serum-free medium (SFM)
alone (Fig. 4A). Preexposure of HUVECs to NO partially
reversed this effect, restoring GSH concentrations to 93%
of the resting level (Fig. 4A). However, a more than 20%
increase in intracellular GSH pools from baseline was ob-
served in IL-1β-stimulated HUVECs (Fig. 4A). Incuba-
tion with NO prior to activation with IL-1β resulted in a de-
crease in GSH concentrations to the basal level (Fig. 4A).
Hence, cytokine-induced alterations in cellular GSH pools
were prevented by preexposure of HUVECs to NO
donors.
Exogenous NO Does Not Modulate Cytokine-Induced
Endothelial cGMP Production
Nitric oxide exerts its relaxation effect on smooth
muscle cells by activating soluble guanylate cyclase (sGC)
that in turn leads to increased intracellular concentrations
of cyclic GMP (cGMP).(17) To ascertain whether the ob-
served effect of NO on MCP-1 suppression is accom-
panied by increased cGMP levels, we treated HUVECs
with NO donor compounds and measured cellular cGMP
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Fig. 3. Effect of exogenous NO on cytokine-mediated NF-κB translocation and on activation
of AP-1. HUVECs were treated for 30 min with medium (SFM) or a combination of MAHMA
NONOate and DEA NONOate (50µM each), followed by a 45-min incubation period with either
TNF-α or IL-1β respectively. Nuclear extracts were prepared as described in “METHODS” and
were incubated in presence of a radiolabeled NF-κB or AP-1 consensus oligonucleotide probe
for 30 min at room temperature. Samples were run on a nondenaturing 4% polyacrylamide gel.
Competition with a 50-fold excess of unlabeled (cold) NF-κB or AP-1, respectively, abrogated
the gel shift (data not shown).
levels. In HUVECs, NO treatment did not significantly
alter the intracellular concentration of cGMP measured at
15 min after exposure (Fig. 4B, HUV). This is in contrast
to smooth muscle cells in which cGMP levels began to
rise by 15 min (Fig. 4B, SMC). These data suggest that
NO-mediated suppression of TNF-α and IL-1β-induced
MCP-1 expression in endothelial cells is not mediated by
sGC. This observation, in conjunction with the above data,
is consistent with the hypothesis that NO-mediated sup-
pression of cytokine-induced MCP-1 expression is medi-
ated by a redox-sensitive mechanism.
Inhibition of Endothelial NO Synthesis Increases
Cytokine-Induced MCP-1 Secretion
The effect of inhibition of endothelial NO synthesis
on TNF-α-mediated MCP-1 expression was studied using
L-NG-nitroarginine methyl ester (L-NAME), an inhibitor
of nitric oxide synthase. HUVECs treated with medium
alone secreted low concentrations of MCP-1 (Fig. 5). A
significant rise in MCP-1 concentration was detected in
cells exposed to either 1ng/mL or 10 ng/mL, respectively,
of TNF-α (Fig. 5). Pretreatment of HUVECs with 4 mM,
1 mM, and 250µM L-NAME, respectively, resulted in
significant increases in TNF-α mediated MCP-1 secretion
(Fig. 5). Concentrations of L-NAME less than or equal to
62.5µM were ineffective in modulating MCP-1 secre-
tion (Fig. 5). These data suggest that inhibition of cellu-
lar nitric oxide production results in an augmentation of
MCP-1 concentration and that endogenously synthesized
NO plays an important role in regulating cytokine-induced
MCP-1 expression.
iNOS Knockout Exhibit Increased Pulmonary
MCP-1 Concentrations
We have previously decribed the time course for pul-
monary MCP-1 expression following glucan infusion (9).
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Fig. 4. Effect of NO donors on intracellular GSH pools in HUVECs (A) and cGMP pools in HUVECs and SMCs (B). Endothelial and
smooth muscle cells were treated with a combination of MAHMA and DEA NONOate (50µM each). GSH and cGMP determinations
were performed as described in “METHODS.” The data shown is representative of three separate experiments. Asterisk* denotes
significant difference in GSH and cGMP concentrations in presence and absence of NO donor. HUV= human umbilical vein
endothelial cells; SMC= human vascular smooth muscle cells.
Here, MCP-1 concentrations following intravenous glu-
can administration were measured in the lungs of BL6
wild type and strain-mutatediNOS knockout mice. As
shown in Fig. 6, immediately following glucan-infusion
to BL6 wild-type mice, virtually no MCP-1 was detected
in the lungs (time 0). At 1.5 h after glucan infusion,
MCP-1 concentrations were significantly elevated. Pul-
monary MCP-1 concentrations peaked at 24 h. At 96 h
after glucan infusion, a return towards baseline MCP-1
concentration was observed. IniNOSknockout mice, pul-
monary MCP-1 concentrations followed a similar tem-
poral pattern with a peak at 24 h and a decline towards
baseline concentrations at 96 h post glucan infusion. How-
ever, when compared to wild-type controls, pulmonary
MCP-1 concentrations iniNOSknockout mice were sig-
nificantly elevated at 0 and 24 h following glucan infusion.
These data suggest that in mice, the absence of inducible
nitric oxide synthase results in augmented pulmonary
MCP-1 concentrations at baseline and following glucan
infusion.
DISCUSSION
The present data indicate that exposure of ECs to NO
prior to TNF-α or IL-1β-induced activation significantly
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Fig. 5. Effect of endogenous NOS inhibition on cytokine-mediated MCP-1 expression. HUVECs were treated
with medium or the indicated concentrations of L-NAME, respectively, for 2 h. The cells were subsequently
incubated in presence of medium alone or TNF-α at either 1ng/mL or 10 ng/mL, respectively for 8 h. At the
end of this incubation period, conditioned media were removed and subjected to MCP-1 EIAs. The data shown
is representative of three separate experiments, each performed in triplicate. Asterisk∗ d notes significant (at
α = 0.05) difference from MCP-1 concentrations in TNF-α-stimulated endothelial cells as determined by
Bonferroni comparison of means.
suppresses expression of MCP-1. Conversely, inhibition
of endogenous nitric oxide synthesis by L-NAME re-
sults in signficant increases in cytokine-induced MCP-1
concentrations. Consistent results were also observed
in a rodent model of pulmonary granulomatous vas-
culitis. The lungs of iNOS knockout mice exhibited
substantially greater concentrations of MCP-1 following
intravenous glucan administration than did those of wild-
type mice suggesting that NO is an important regula-
tor of MCP-1 expression during granuloma formation.
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Fig. 6. Pulmonary MCP-1 concentrations in wild type (¤) and iNOS knockout mice (¥) at varying time points following intravenous
glucan administration. Mice were sacrificed at the indicated times after glucan infusion and lung extracts were subjected to MCP-1
EIAs. Three animals were used per time point and each sample was analyzed in triplicate. Asterisk∗ denotes significant difference
(p < 0.05) in pulmonary MCP-1 concentrations between iNOS and BL6 mice at the indicated time points following glucan infusion.
This study also suggests that the redox-sensitive tran-
scription factor NF-κB, but not AP-1, is associated with
the NO-mediated suppression of cytokine-induced MCP-
1 expression. Futhermore, treatment of HUVECs with NO
donors did not significantly alter the intracellular con-
centration of cGMP, suggesting that the NO-mediated
suppression of TNF-α and IL-1β-induced MCP-1 ex-
pression in endothelial cells is not mediated by sol-
uble guanylate cyclase (sGC). Exogenously supplied
NO, however, reversed cytokine-induced alterations in
intracellular GSH concentrations lending further sup-
port to the hypothesis that the NO-mediated suppres-
sion of cytokine-induced MCP-1 expression is medi-
ated by a redox-sensitive mechanism. Our data agree
with recent reports from several other laboratories. Zei-
her et al. (18) reported that inhibition of basal NO pro-
duction in ECs by the NOS inhibitor NG-nitro-L-arginine
(L-NAG) increased MCP-1 mRNA levels to 250±
20% of controls and resulted in a marked increase in mono-
cyte chemotactic activity. As in this study, generation of
exogenous NO resulted in a decrease in MCP-1 at both
the protein and mRNA levels (18). Tsaoet al. (19) ob-
tained similar results in rabbit aortic smooth muscle cells
that were stimulated with lipopolysaccharide (LPS) or ox-
idized LDL (oxLDL) (19). Khanet al. (20) reported that
NO donors also reduce VCAM-1 and ICAM-1 expression
in endothelial cells at both the protein and mRNA lev-
els (20). Taken collectively, these studies suggest that NO
regulates the expression of inflammatory mediators (i.e.
adhesion molecules and chemokines) and that the mech-
anism by which NO suppresses inflammatory mediator
expression may involve an inhibition of the cytosolic-to-
nuclear translocation of the redox-sensitive transcription
factor NF-κB.
Several recent studies aimed at unraveling the mech-
anism(s) by which exogenous NO may inhibit NF-κB
translocation, however, are in conflict. Katsuyamaet al.
(21) observed that in rat vascular smooth muscle cells,
the inhibitory effect of NO on NF-κB activation occurs
through inhibition of IκB-α phosphorylation (21). On the
other hand, Penget al. (22) reported that NO donors inhibit
TNF-α-induced NF-κB activation in human saphenous
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vein endothelial cells by induction and stabilization of
IκB-α (22). In addition, NO also increased the mRNA
expression of IκB-α. This group of investigators subse-
quently reported that the inhibition of NF-κB activation
by NO occurs via increases in cytoplasmic and nuclear
concentrations of IκB-α. The discrepancies in these ob-
servations may be accounted for by the different cell types,
species, cytokines, and NO donors used (21, 23). Recent
in vitro studies published by Umanskyet al. (24) indi-
cate that the effect of NO on NF-κB activation may be
concentration dependent. Low concentrations of the NO-
generating compound glycerol trinitrate (GTN) enhanced
TNF-α or PMA-induced NF-κB binding activity and
transactivation in endothelial TC 10 cells which was asso-
ciated with increased activation of IκB-α kinase (IKK-α)
(24). NO at high concentrations (>250µM) on the other
hand, repressed NF-κB-dependent transactivation almost
to the basal level. Since iNOS expression itself is activated
by NF-κB these data illustrate that low concentrations of
NO provide a self-amplifying signal in the inflammatory
response (23, 25).
Our observation that NO blunts TNF-α and IL-1β-
induced fluctuations in intracellular-reduced glutathione
pools provides additional evidence in favor of the hypoth-
esis that NO-mediated modulation of endothelial MCP-1
expression occurs through a redox-sensitive mechanism.
In an in vitro analysis of the role of NO in modula-
tion of neutrophil-endothelial interactions, Niuet al. (26)
reported that exposure of HUVECs to NO results in a
decrease in ICAM-1 expression (26). Conversely, incu-
bation of HUVECs with the NOS inhibitor L-NAME
resulted in an increase in both platelet-activating factor
and ICAM-1-mediated neutrophil adhesion (26). Through
the use of 2′, 7′-dichlorodihydro-fluorescein diacetate-
loaded HUVECs and a series of intracellular and ex-
tracellular oxygen radical scavengers these researchers
concluded that NO-mediated effects on endothelial cell
adhesion molecule expression occurred via a redox-
sensitive mechanism (26). Our previous studies in a rat
model of glucan-induced granulomatous vasculitis sug-
gest that neutrophil-derived reactive oxygen intermediates
modulate the expression of MCP-1 in pulmonary blood
vessel wall cells (7). Thein vivodata presented here com-
plement the larger body ofin vitro data suggesting a path-
way by which NO may delimit angiocentric granuloma
formation. Exposure of unactivated endothelial cells at
the margins of a developing granuloma to the relatively
high local concentrations of NO produced by recruited
monocytes and macrophages may render these endothe-
lial cells less responsive to proinflammatory stimuli such
as TNF-α and IL-1β, This hypothesis is supported by the
in vitro data that indicate that preexposure, but not si-
multaneous or later exposure, of HUVECs to NO renders
them less responsive to TNF-α and IL-1β with respect to
MCP-1 expression. This action of NO may be mediated
by resistance to changes in EC redox status.
In the context of an evolving granuloma these obser-
vations and the report by Umanskyet al. (24) suggest that
low concentrations of NO released by recruited, activated
monocytes may amplify the expression of inflammatory
mediators (24). As monocyte numbers increase to a critical
mass, high local concentrations of NO may down-regulate
the inflammatory response. This study supports the idea
that by down-regulating the expression of critical inflam-
matory mediators (i.e. adhesion molecules, chemokines,
and cytokines) NO may play an important role in processes
that lead to the delimitation and resolution of granuloma-
tous lesions in the lung.
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